TafluprostSaflutan
Treatment of ocular hypertension and primary open-angle glaucoma, as monotherapy or adjunctive therapy.
Decision on record
- Meeting Mar 2012 Recommended Glaucoma
Access path
- TGA registered · Saflutan
TGA label narrower than the PBS population
- Mar 2012Recommended · restricted
Comparator changed: latanoprost 0.005% with preservative (latanoprost-P) → latanoprost…
- Mar 2012Recommended · restricted
Comparator changed: latanoprost 0.005% with preservative (latanoprost-P) → latanoprost…
- PBS listing · Unrestricted
Cost-effectiveness
Cost-minimisation analysis (cost comparison only); no ICER calculated as non-inferiority was not accepted.
The PBAC considered that the net costs of listing tafluprost-PF were uncertain. PBAC · 2012
Decision context
PopulationAdults with ocular hypertension or primary open-angle glaucoma requiring topical therapy; specifically those intolerant of benzalkonium chloride preservative or experiencing ocular signs/symptoms with preserved prostaglandin analogues.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2012 | Recommended · restricted | latanoprost 0.005% with preservative (latanoprost-P) | — | RCT, Single-arm · IOP reduction |
| Mar 2012 | Recommended · restricted | latanoprost with preservative (latanoprost-P) | — | RCT · IOP |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients who failed latanoprost-P after 6+ months, whereas TGA label permits use as initial monotherapy or adjunct.